IGF1 and acromegaly: In this 52-year-old patient, in whom combined treatment with octreotide and cabergoline failed to normalise IGF-1 levels, switching to pasireotide LAR successfully normalised her IGF-1 levels and resolved all signs of active acromegaly, with only transient side effects following the first injection, with an added benefit of tumour size reduction not achieved before by the combination of a first-generation SRL and dopamine agonist therapy.